CATX: Perspective Therapeutics Inc Year-over-year earnings per share growth for the last twelve months

The development of innovative alpha-therapy and successful clinical trials are complemented by the seamless operation of sterile laboratories for the synthesis of radiopharmaceuticals. Quarterly EPS dynamics demonstrate the real efficiency of the business, with the 22.90 mark characterizing this parameter. The stability of Perspective Therapeutics (CATX) relies on the synergy of precision medicine supported by the world's leading scientific centers.

Perspective Tx (CATX) - Quarterly EPS earnings growth from 06/21/2023 to 11/13/2026

Analytical breakdowns for Perspective Therapeutics (CATX)

- market value and analyst target forecast:

Price Chart perspectivetherapeutics.com|CATX - Forecast Levels Chart

- market capitalization information:

Market Value Perspective Therapeutics Inc|CATX - Total Company Value

- book capitalization data:

Book Value per Share Perspective Therapeutics|CATX - Book Capitalization|Market Cap to Net Assets Ratio perspectivetherapeutics.com|CATX - Aggregate Business Assets

- debt burden and liquidity indicators:

Total Debt to Capital Perspective Therapeutics|CATX - Long-Term Liabilities to Equity|Short-Term Debt to Equity perspectivetherapeutics.com|CATX - Company Cumulative Debt|Debt to Book Capitalization Ratio Perspective Therapeutics Inc|CATX - Company Long-Term Loans and Borrowings|Company Short-Term Debt Perspective Therapeutics|Quick Liquidity perspectivetherapeutics.com

- earnings and valuation multiples indicators:

CATX - Net Financial Result|Expected Profit Perspective Therapeutics|CATX - Market Cap to Net Income|Forward P/E Multiple perspectivetherapeutics.com|CATX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Perspective Therapeutics Inc|CATX - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Perspective Therapeutics|CATX - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months perspectivetherapeutics.com|CATX - Earnings per share trend in current year|Earnings growth forecast for next year Perspective Therapeutics

Comprehensive company analysis:Perspective Therapeutics

Flagship merchandise of perspectivetherapeutics.com

Asset reliability is determined by a business's ability to generate growing cash flow. This indicator measures the percentage change in net earnings per share per quarter, reflecting the dynamics of real returns. For Perspective Therapeutics (CATX), this calculation demonstrates the effectiveness of investments in radiopharmaceuticals and oncology research. Profit growth confirms the successful scaling of the platform. By analyzing the quarterly EPS growth rate, an investor determines the fairness of the current market valuation.

Who Perspective Therapeutics competes with

Geron (GERN) - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months NBTX (Nanobiotix SA)|Year-over-year earnings per share growth for the last twelve months Bicycle Pharma|Year-over-year earnings per share growth for the last twelve months CTMX|Quarterly EPS earnings growth GNLX|Quarterly EPS earnings growth Molecular Partners Ltd (MOLN)|Oncolytics Biotech - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months LSTA (Lisata Therapeutics Inc.)|Moleculin - Quarterly EPS earnings growth|Year-over-year net earnings per share trend for the last twelve months GRTX|Molecular Templates (MTEM) - Year-over-year earnings per share growth for the last twelve months